1. Home
  2. RMCO vs NNVC Comparison

RMCO vs NNVC Comparison

Compare RMCO & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royalty Management Holding Corporation

RMCO

Royalty Management Holding Corporation

HOLD

Current Price

$2.66

Market Cap

37.9M

Sector

Miscellaneous

ML Signal

HOLD

NNVC

NanoViricides Inc.

HOLD

Current Price

$1.02

Market Cap

35.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCO
NNVC
Founded
2021
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
35.2M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
RMCO
NNVC
Price
$2.66
$1.02
Analyst Decision
Buy
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.2K
261.9K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
0.35%
N/A
EPS Growth
N/A
10.00
EPS
N/A
N/A
Revenue
$4,949,916.00
N/A
Revenue This Year
$209.10
N/A
Revenue Next Year
$133.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
513.30
N/A
52 Week Low
$1.74
$0.85
52 Week High
$5.00
$2.23

Technical Indicators

Market Signals
Indicator
RMCO
NNVC
Relative Strength Index (RSI) 47.36 19.26
Support Level $2.64 $0.86
Resistance Level $3.04 $1.07
Average True Range (ATR) 0.22 0.06
MACD -0.03 -0.02
Stochastic Oscillator 20.72 2.26

Price Performance

Historical Comparison
RMCO
NNVC

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Share on Social Networks: